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ABSTRACT
Polymorphisms of proteins which have an important role in drug transport, metabolism, and disposition in the body
could affect the drugs efficacy and toxicity. The organic cation transporter 1 (OCT1), encoded by SLC22A1 gene,
has been known as one of the polyspecific protein transporters which could affect some of the cationic drug
response such as metformin, levodopa and imatinib. However, the findings of many studies an association of OCT1
polymorphisms and drug response both in Caucasian and Asian were still inconsistent. Moreover, this study’s topic
in Asians was still uncommon. This review was aimed to explore the polymorphisms of OCT 1 in Asians and Caucasians
and to find the challenges of the next studies in Asians. The articles about OCT1 polymorphisms were searched in
the PubMed with the keywords; OCT1 or SLC22A1, polymorphisms. There were ten articles of OCT1 polymorphisms
which are related to the drug response and most of the studies were performed in Caucasian subjects. In Caucasians,
the rs622342 variant might associated with the response of metformin and levodopa. Moreover, the R61C and
420del variants still showed the inconsistent findings associated with metformin response. The non-synonymous
variants which were found in Caucasians were not found in Asian. However, the new non-synonymous variants
were found in Japanese, Chinese, Indian and Korean population and some of them were associated with the metformin
response. The recent findings found in Caucasians cancer patients, were related to the association of non-synonymous
variants haplotype and the 5-Hydroxytriptamine Receptor Antagonists drug response. The inconsistent results of
OCT1 polymorphisms studies could be related to the study’s sample size and design of the studies. Further studies
which exploring the association of OCT1 polymorphisms and drug pharmacokinetic profiles and/or drug response,
which were adjusted by genetic variants of proteins involved in drug tansport, metabolism and disposition are still
needed in both Caucasians and Asians. Additional large studies also considering non-genetic risk factors are warranted,
to implement the results of the various studies into clinical practice.
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ABSTRAK
Polimorfisme protein yang berperan penting dalam transport, metabolisme dan disposisi obat dalam tubuh dapat
mempengaruhi efektivitas dan toksisitas obat. Organic cation transporter 1 (OCT1) yang dikode oleh gena SLC22A1,
dikenal sebagai salah satu transporter protein polispesifik yang dapat mempengaruhi respon obat kationik seperti
metformin, levodopa dan imatinib. Namun demikian, banyak penelitian menunjukkan hubungan polimorfisme OCT1
dan respon obat baik pada orang Kaukasoid dan Asia tidak konsisten. Selain itu penelitian mengenai hal ini pada
orang Asia masih jarang. Tinjaun pustaka ini bertujuan untuk mengkaji polimorfisme OCT1 pada orang Asia dan
Kaukasoid dan kemungkinan dilakukannya penelitian pada orang Asia. Pustaka mengenai polimorfisme OCT1 diperoleh
dari PubMed menggunakan kata kunci OCT1, SLC221 dan polimorfisme. Terdapat 10 artikel polimorfisme OCT1
yang berkaitan dengan respon obat dan sebagian besar dilakukan pada subjek Kaukasoid. Pada orang Kaukasoid,
varian rs622342 kemungkinan berhubungan dengan respon metformin dan levodopa. Lebih jauh, varian R61C dan
420del masih menunjukkan hubungan yang tidak konsisten. Varian non-synonymous yang ditemukan pada orang
Kaukasoid tidak ditemukan pada orang Asia. Namun demikian varian non-synonymous ditemukan pada populasi
Jepang, Cina, India dan Korea. Beberapa diantaranya dihubungkan dengan respon metformin. Penemuan terkini
ditemukan pada penderita kanker orang Kaukasoid dan berhubungan dengan varian non-synonymous haploid dan
respon obat antagonis reseptor hidroksitriptamin-5. Ketidakkonsisten hasil penelitian polimorfisme OCT1 kemungkinan
dapat dikaitkan dengan jumlah sampel dan rancangan penelitian. Penelitian lebih lanjut untuk menghubungkan
polimorfisme OCT1 dan profil farmakokinetik dan atau respon obat yang dikendalikan oleh variasi genetik protein
yang terlibat dalam transport, metabolisme, disposisi obat masih diperlukan baik pada orang Kaukasoid dan Asia.
Penelitian yang lebih luas juga perlu dilakukan dengan mempertimbangkan faktor risiko no-genetik untuk dapat
mengimplementasikan hasil berbagai penelitian dalam praktek klinik.
Kata kunci : OCT1- polimorfisme – orang Asia – orang Kaukasoid - respon obat
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INTRODUCTION
The drug efficacy and toxicity could be affected
by the variability of genes encoding proteins which
have role in drug absorption, distribution,
metabolism and excretion.1,2 Organic Cation
Transporter 1 (OCT1) is one of the polyspesific
transporters which has important role in translocating
drugs, toxins and neurotransmitter with cation
organic structure.3,4 The OCT1, encoded as
SLC22A1 was mostly found in the liver and was
less expressed in kidney and human intestine.5 The
SLC22A1 mediates the transport of small molecular
weight hydrophylic organic cation from extracellular
fluid to the hepatocyte.6 Therefore, the poly-
morphism of OCT1 gene could affect the pharmaco-
kinetic parameters of the drug which were mainly
metabolized in the liver and consequently, the
response of the drugs would be affected as well.
This polymorphism could increase the risk of
adverse drug reactions because the concentrations
of the drug in the serum may exceed the minimal
toxic concentration or may decrease the drug
response.7 In the other hand, the OCT1 also has
role in detoxification of xenobiotics and chemoterapy
agents.8 Some of the drugs were known as substrate
of this gene, like metformin, amantadine and
pramipexole.9-10 Recently, the study about metformin
found that eventhough this drug is not metabolized
and available in cationic form, it is largely
transported into hepatocytes and renal tubular
epithelium by OCT1.11-12 One of the study of
metformin pharmacogenetics showed that the variant
of rs622342 of OCT1 gene could modify the
metformin response to the blood glucose level.
Furthermore, the multidrug and toxin extrusion
transporter (MATE1) gene was known to increase
the antihypergycemic effect of metformin.12 This
finding was supported by studies in Caucasian which
identified the OCT1 polymorphisms which were
related to the decrease effect of metformin.13-14 The
other previous study also found that the OCT1
polymorphisms could predict the response of
imatinib in chronic myeloid leukemia and the survival
rate of patients used levodopa as anti-parkinson.9,15
However, the effect of OCT1 polymorphisms to the
drug response in Asian is still being a challenge to
the researcher. The previous studies in Japanese
and Chinese found that the reduced-functions coding
region of OCT1 variants was more rare than those
of Caucasians. Furthermore, these rare variants may
alter the response of metformin as well.16
The aim of this review was to explore the poly-
morphisms of OCT 1 in Asians and Caucasians and
to find the challenges of the next studies in Asians.
MATERIALS AND METHODS
The articles about OCT1 polymorphisms in the
PubMed with the keywords; OCT1 or SLC22A1,
polymorphisms were searched. Ten articles of OCT1
polymorphisms which are related to the drug
response were found and most of the studies were
performed in Caucasian subjects.
RESULTS
The studies related to the OCT1 polymorphisms
and drug response are listed in TABLE 1. Two
studies were performed in Asians and the others
were performed in Caucasians. To date, with the
limited number of OCT1 polymorphism studies in
Asian, the challenge of the topic is still opened.
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TABLE 1. Studies of the OCT1 polymorphisms and drug response
DISCUSSION
Most of the studies in the TABLE 1 were based
on association of OCT1 polymorphisms and
metformin. Metformin mechanism was supposed
to be related to activation of AMP-activated protein
kinase (AMPK). This activation will suppress
glucagon-stimulated glucose production, then it will
increase the glucose-uptake in muscle and hepatic
cells. The OCT1 variants was supposed to mediate
metformin response in the first step of metformin
action which involved the activation of AMPK.17
In the study of Caucasian patients with diabetes
mellitus, the subjects with minor C allele of rs622342
experienced less response of metformin in reducing
HbA1Cand glucose levels.13 In the other hand, the
other study in Caucasian patients of diabetes mellitus
found that the two reduced functions of OCT1
polymorphisms, R61C and 420del, did not alter the
metformin response in reducing HbA1C.14 Contra-
Author (year) Variants Drug  Subject Outcome Result 
Zhou et al., 2009 R61C and 
420del 
Metformin  Caucasian Reduction of HbA1C  
level 
These polymorphisms 
did not alter metformin 
response 
Becker et al., 
2009 
rs622342 Metformin  Caucasian Reduction of glucose 
level and HbA1C level 
The subject with minor 
C allele experienced 
less response of 
metformin 
Tzvetkov et al., 
2009 
R61C, 
G410S, 
G465R, 
M420del 
Metformin Caucasian Renal clearance and 
plasma concentration 
Subject with higher 
number of active alleles 
showed lower renal 
clearance and higher 
metformin plasma 
concentration 
Kim et al., 2009 rs683368 Imatinib 
mesylate 
Caucasian Laboratory test of 
imatinib response 
GG genotype of the 
rs683368 was 
associated with less 
response of imatinib 
Jablonski et al., 
2010 
rs622342 Metformin Caucasian Development of diabetes 
disease 
The rs622342 had no 
interaction with 
metformin intervention 
Chen et al., 2011 Q97K, 
P117L and 
R206C 
Metformin Japanese and 
Chinese 
Michaelis- Menten 
parameter and uptake of 
metformin in cells 
1.The uptake of 
metformin in cells by 
these variants was 
reduced significantly 
2. P117 and R206C 
showed reduction of 
Vmax. 
3. Q97K showed the 
increase of Km 
Becker et al., 
2011 
rs622342 Levodopa Caucasian Survival time The subject with minor 
C allele had shorter 
survival time 
Tzevetkov et al., 
2012 
R61C, 
C88R, 
G410S, 
G465R, 
M420del 
Ondansetron 
and tropisetron 
Caucasian Mean episode of 
vomiting after 
chemotherapy 
Subjects with higher 
number of active alleles 
experienced more 
episode of vomiting 
than subjects with 
wildtype 
Choi et al., 2012 P283L, 
P341L 
Metformin and 
lamivudine 
Korean The Clearance of 
metformine and 
lamivudine 
Lamivudine uptake  
decreased in the 
variants of OCT1. 
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dictively, the previous study in Caucasian showed
that the subjects with the variants of R61C and
420del experienced the higher of area under the
plasma concentration-time curve and higher
maximum plasma concentration.18 The different
result of these two previous studies could be caused
by the number of sample included in the study or
the different design of study. The other study by
Tzvetkov et al in Caucasian subjects also found
that subject with higher number of active allele
showed lower renal clearance and higher metformin
plasma concentration. This study included R61C,
G410S, G465R, M420del as the variants and were
predicted as active and inactive function, such as
OCT1*1 (active), *2, *3, *4 and *5 (inactive).19
Those allele variants could alter the disposition of
OCT1 substrate. Therefore, the drug response will
be changed.20 The result of the metformin response
study in Caucasian woman with polycystic ovarian
syndrome which included similar SNPs also
consistent with the Tzvetkov et al study.21 In the
future perspective, to conduct the study which
exploring the pharmacokinetic parameters of
metformin with considering the reduction of glucose
levels and HbA1C levels is still being a good challenge
in Caucasian.
In the study of metformin response in the
Diabetes Prevention Program, there were 40 genes
explored to understand the associations between the
gene variants and metformin response. Most of the
subjects in this study were Caucasians (55.9%) and
4.3% of Asians. The variants of OCT1 which was
associated to the metformin response were still
robust. The SNP with rs622342 showed no
interaction with metformin response.22 The different
results of this study and the study of Becker et al.9
could be caused by the different condition of subjects
participated in the studies. The expression of OCT1
is in the small intestine and small amount in the
brain. The expression of OCT1 which involved in
the differences of levodopa response was unknown.
Therefore, to consider further study on rs622342
and exploring its association with glucose levels and
HbA1C levels or considering the pharmacokinetic
parameters of metformin is needed.
The study of OCT1 polymorphism in Japanese
and Chinese was conducted in understanding its role
in metformin response. Nine SNPs were included
in this study; -43T>G, S14F, R61C, S189L, G220V,
G410S, V408M, 420del and G465R. The study also
identified the other non-synonymous variants. This
study found that not all of the variants with decrease
function in Caucasians were found in Japanese and
Chinese patients with type 2 diabetes melitus. The
nonsynonymous variants found in this study, Q97K,
P117L and R206C, were associated with the
reduced function of OCT1. Thus the uptake of
metformin in subjects with these variants were
significantly reduced.16 We can conclude that the
decreased functions of OCT1 variants in Caucasians
were not found in Asians, furthermore the other
nonsynonymous decreased functions of OCT1
variants were found in Japanese and Chinese with
type 2 diabetes mellitus. The other study in Indian
population found that P341L, M408V and 1386C>A
variants in South Indian Tamilian. The allele
frequencies of P341L and M408V were similar to
the allele frequencies of Japanese and Korean
population. However, the 1386C>A was not found
in Japanese and Korean. The allele frequencies of
P341L in Chinese and Vietnam population were
lower than those in Indian. Nevertheless, there were
no variants of M408V and 1386C>A found in
Chinese and Vietnam. In Caucasian, the variants of
P341L and 1386C>A were not found.23 The other
study reported that after haplotype analysis, the
distribution of SNPs in Korean, Japanese and
Chinnese were similar.24 This could be challenging
for the next studies in Asians to find the new variants
of OCT1 which play role in drug response.
Imatinib, was largely used in treatment of
chronic myeloid leukemia (CML). Around 20% CML
patients did not get satisfactory response of imatinib
because of the resistance.25 The drug transporter
variability was proposed as the variability of imatinib
response. The active uptake of imatinib into cells
was transported by OCT1 and this agent was
metabolized by CYP3A4 and CYP3A5.26 It was
known that the drug disposition was mainly
dependent on the role of liver metabolic enzymes
and drug transporter. Imatinib was the weak
substrate of OCT1 and the role of OCT1 was more
related as surrogate expression of the others
intracellular uptake transporter.27 It was proved by
pharmacogenetic study of imatinib in CML patients
which showed that the GG genotype of rs683368
was associated to the loss response of imatinib
together with the other predictive factors , such as
142
J Med Sci, Volume 43, No. 2, June 2011: 138-144
rs2231137 of ABCG2 and the genotype of
CYP3A5.15
The other previous study in Caucasian subjects
was aimed to know the associations betweeen OCT1
variant of rs 622342 and the anti-parkinson drugs
efficacy. Subjects who were prescribed levodopa for
the first time were included in this study.28 Levodopa
is a substrate of OCT, eventhough the specific
transporter is not clearly defined yet.9,28 This study
found that the subjects with minor C allele needed
higher dose of prescribed anti-parkinson drug and also
had shorter survival time after levodopa prescription.
However, the authors of this study mentioned that the
replication of this study will be needed because of the
small number of participants might increase the the
possibility of false-positive findings.9 According to the
two previous mentioned studies in the metformin
response, we could find that the minor C allele of
rs622342 of OCT1 may express the decrease function
of OCT1 both in metformin and levodopa responses.
The rs622342 was located in intron and it was known
that this region had linkage of disequilibrium with the
functional alleles.9 This fact could affect the gene
expression.
The recent study of OCT1 role was performed
by Tzvetkov et al.29 toward ondansetron and
tropisetron. The previous review found that the
response of 5-Hydroxytriptamine Receptor Antagonists
in Caucasian cancer patients could be affected by the
polymorphisms of the 5-Hydroxytriptamine receptors,
the Multi Drug Resistence 1 (MDR1) as the protein
transporter uptake and CYP2D6.30 Ondansetron and
tropisetron were partly metabolized by CYP2D6, and
these agents are being the OCT1 substrate. The R61C,
C88R, G410S, G465R and M420del amino acid
substitutions were included in Tzvetkov et al.29 study.
They performed the haplotype of these combinations
and predicted the phenotype of the haplotype as fully
active function and deficient function. This study
concluded that the wildtype of OCT1 showed less
clinical efficacy of tropisetron than the two loss of
functional variants. The tropisetron serum
concentrations was higher in subjects with two loss of
functional variants than those of wildtype. The effect
of OCT1 genotype was significantly higher in
tropisetron than in ondansetron.29 The previous study
in Asians, showed that there were no associations
between the polymorphisms of MDR1, 5-
Hydroxytriptamine B receptors and the CYP2D6
predicted phenotypes and the ondansetron.31 According
to the study result of Tzvekov et al.29 this could be a
challenge to know the association of OCT1
polymorphisms and the ondansetron or tropisetron
response in Asians, since there were still around 30%
patients did not get satisfactorily response of
ondansetron in acute phase of chemotherapy-induced
nausea-vomiting.31
The newest study in Korean population, found
that the P283L and P341L variants of OCT1 could
decrease the uptake of lamivudine.32 The pharmaco-
genetic study of lamivudine is still limited. The previous
study about pharmacogenetic of lamivudine was aimed
to know the association between tumor necrosis factor-
alpha promoter and lamivudine response. This study
found that the non-responsive patients could be related
to the variants of this gene.33 It means that, lamivudine
pharmacokinetic parameters information related to the
pharmaco-genetic studies must be available to support
the application of pharmacogenetic studies of
lamivudine in clinical settings. However, the other genes
which have role in lamivudine absorption, distribution,
metabolism and excretion should be involved in the
next studies.
CONCLUSION
The studies of OCT1 polymorphisms are going
to widespread in the next further years. To apply the
result findings in the metformin individualized therapy,
we have to consider the ethnicities differences, because
the non-synonymous variants found in Caucasians did
not found in the Asians.However, the new non-
synonymous variants were found in Asians and affected
the metformin response. The studies about imatinib
response and 5-Hydroxytriptamine Receptor
Antagonists response will be the challenge in Asian.
However, it is too early to implement the results of the
various studies into clinical practice. Additional large
studies also considering non-genetic risk factors are
warranted.
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